Key regions: Australia, Germany, United Kingdom, United States, France
Ghana, a country in West Africa, has a developing healthcare industry that is witnessing a growing market for immunosuppressants.
Customer preferences: The demand for immunosuppressants in Ghana is primarily driven by the increasing prevalence of autoimmune diseases and organ transplant procedures. Patients suffering from autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis require long-term treatment with immunosuppressants to manage their symptoms. Additionally, the country's healthcare system has seen a rise in the number of organ transplant procedures, which also require the use of immunosuppressants to prevent organ rejection.
Trends in the market: The immunosuppressants market in Ghana is witnessing a trend towards the use of generic drugs due to their lower cost and wider availability. However, the lack of regulation in the country's pharmaceutical industry has led to concerns about the quality and safety of these drugs. As a result, there is a growing need for increased regulation and oversight to ensure that patients have access to safe and effective drugs.
Local special circumstances: Ghana's healthcare industry faces several challenges, including a shortage of healthcare professionals, inadequate healthcare infrastructure, and limited access to healthcare services in rural areas. These challenges have led to a growing demand for telemedicine and other digital health solutions, which have the potential to improve access to healthcare services and increase patient outcomes.
Underlying macroeconomic factors: Ghana's economy has been growing steadily in recent years, with a focus on diversification and industrialization. The country's healthcare industry has also seen significant investment, with the government increasing its healthcare spending and encouraging private sector investment in the sector. These macroeconomic factors have contributed to the growth of the immunosuppressants market in Ghana and are expected to continue to drive growth in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
